Impact of Frailty on Surgical Outcomes of Patients With Cushing Disease Using the Multicenter Registry of Adenomas of the Pituitary and Related Disorders Registry.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
10 Jul 2024
Historique:
received: 02 01 2024
accepted: 10 05 2024
medline: 10 7 2024
pubmed: 10 7 2024
entrez: 10 7 2024
Statut: aheadofprint

Résumé

Despite growing interest in how patient frailty affects outcomes (eg, in neuro-oncology), its role after transsphenoidal surgery for Cushing disease (CD) remains unclear. We evaluated the effect of frailty on CD outcomes using the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) data set from a collaboration of US academic pituitary centers. Data on consecutive surgically treated patients with CD (2011-2023) were compiled using the 11-factor modified frailty index. Patients were classified as fit (score, 0-1), managing well (score, 2-3), and mildly frail (score, 4-5). Univariable and multivariable analyses were conducted to examine outcomes. Data were analyzed for 318 patients (193 fit, 113 managing well, 12 mildly frail). Compared with fit and managing well patients, mildly frail patients were older (mean ± SD 39.7 ± 14.2 and 48.9 ± 12.2 vs 49.4 ± 8.9 years, P < .001) but did not different by sex, race, and other factors. They had significantly longer hospitalizations (3.7 ± 2.0 and 4.5 ± 3.5 vs 5.3 ± 3.5 days, P = .02), even after multivariable analysis (β = 1.01, P = .007) adjusted for known predictors of prolonged hospitalization (age, Knosp grade, surgeon experience, American Society of Anesthesiologists grade, complications, frailty). Patients with mild frailty were more commonly discharged to skilled nursing facilities (0.5% [1/192] and 4.5% [5/112] vs 25% [3/12], P < .001). Most patients underwent gross total resection (84.4% [163/193] and 79.6% [90/113] vs 83% [10/12]). No difference in overall complications was observed; however, venous thromboembolism was more common in mildly frail (8%, 1/12) than in fit (0.5%, 1/193) and managing well (2.7%, 3/113) patients (P = .04). No difference was found in 90-day readmission rates. These results demonstrate that mild frailty predicts CD surgical outcomes and may inform preoperative risk stratification. Frailty-influenced outcomes other than age and tumor characteristics may be useful for prognostication. Future studies can help identify strategies to reduce disease burden for frail patients with hypercortisolemia.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Despite growing interest in how patient frailty affects outcomes (eg, in neuro-oncology), its role after transsphenoidal surgery for Cushing disease (CD) remains unclear. We evaluated the effect of frailty on CD outcomes using the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) data set from a collaboration of US academic pituitary centers.
METHODS METHODS
Data on consecutive surgically treated patients with CD (2011-2023) were compiled using the 11-factor modified frailty index. Patients were classified as fit (score, 0-1), managing well (score, 2-3), and mildly frail (score, 4-5). Univariable and multivariable analyses were conducted to examine outcomes.
RESULTS RESULTS
Data were analyzed for 318 patients (193 fit, 113 managing well, 12 mildly frail). Compared with fit and managing well patients, mildly frail patients were older (mean ± SD 39.7 ± 14.2 and 48.9 ± 12.2 vs 49.4 ± 8.9 years, P < .001) but did not different by sex, race, and other factors. They had significantly longer hospitalizations (3.7 ± 2.0 and 4.5 ± 3.5 vs 5.3 ± 3.5 days, P = .02), even after multivariable analysis (β = 1.01, P = .007) adjusted for known predictors of prolonged hospitalization (age, Knosp grade, surgeon experience, American Society of Anesthesiologists grade, complications, frailty). Patients with mild frailty were more commonly discharged to skilled nursing facilities (0.5% [1/192] and 4.5% [5/112] vs 25% [3/12], P < .001). Most patients underwent gross total resection (84.4% [163/193] and 79.6% [90/113] vs 83% [10/12]). No difference in overall complications was observed; however, venous thromboembolism was more common in mildly frail (8%, 1/12) than in fit (0.5%, 1/193) and managing well (2.7%, 3/113) patients (P = .04). No difference was found in 90-day readmission rates.
CONCLUSION CONCLUSIONS
These results demonstrate that mild frailty predicts CD surgical outcomes and may inform preoperative risk stratification. Frailty-influenced outcomes other than age and tumor characteristics may be useful for prognostication. Future studies can help identify strategies to reduce disease burden for frail patients with hypercortisolemia.

Identifiants

pubmed: 38985563
doi: 10.1227/neu.0000000000003090
pii: 00006123-990000000-01271
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Lodestar Foundation, Barrow Neurological Foundation

Informations de copyright

Copyright © Congress of Neurological Surgeons 2024. All rights reserved.

Références

Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). J Neurosurg. 1964;21(4):318-347.
Lonser RR, Nieman L, Oldfield EH. Cushing's disease: pathobiology, diagnosis, and management. J Neurosurg. 2017;126(2):404-417.
Bunevicius A, Laws ER, Vance ML, Iuliano S, Sheehan J. Surgical and radiosurgical treatment strategies for Cushing's disease. J Neurooncol. 2019;145(3):403-413.
Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27(1):1-15.
Castle-Kirszbaum M, Wang YY, King J, Goldschlager T. Frailty does not preclude surgical success after endoscopic transsphenoidal surgery for pituitary adenomas. Pituitary. 2021;24(6):922-929.
Khalafallah AM, Shah PP, Huq S, et al. The 5-factor modified frailty index predicts health burden following surgery for pituitary adenomas. Pituitary. 2020;23(6):630-640.
Miller BS, Ignatoski KM, Daignault S, et al. A quantitative tool to assess degree of sarcopenia objectively in patients with hypercortisolism. Surgery. 2011;150(6):1178-1185.
Saad M, Salze B, Trillat B, et al. Association between preoperative medication lists and postoperative hospital length of stay after endoscopic transsphenoidal pituitary surgery. J Clin Med. 2022;11(19):5829.
Thommen R, Kazim SF, Cole KL, et al. Worse pituitary adenoma surgical outcomes predicted by increasing frailty, not age. World Neurosurg. 2022;161:e347-e354.
Peterson R, Kandregula S, Jee E, Guthikonda B. Utility of hospital frailty risk score for predicting postoperative outcomes in craniopharyngioma. J Neurooncol. 2022;159(1):185-193.
Huq S, Khalafallah AM, Jimenez AE, et al. Predicting postoperative outcomes in brain tumor patients with a 5-factor modified frailty index. Neurosurgery. 2020;88(1):147-154.
Zhu J, Qiu X, Ji C, Wang F, Tao A, Chen L. Frailty as a predictor of neurosurgical outcomes in brain tumor patients: a systematic review and meta-analysis. Front Psychiatry. 2023;14:1126123.
Martel-Duguech L, Alonso-Jimenez A, Bascunana H, et al. Prevalence of sarcopenia after remission of hypercortisolism and its impact on HRQoL. Clin Endocrinol (Oxf). 2021;95(5):735-743.
Katsuhara S, Yokomoto-Umakoshi M, Umakoshi H, et al. Impact of cortisol on reduction in muscle strength and mass: a mendelian randomization study. J Clin Endocrinol Metab. 2022;107(4):e1477-e1487.
Tracy BM, Carlin MN, Tyson JW, Schenker ML, Gelbard RB. The 11-item modified frailty index as a tool to predict unplanned events in traumatic brain injury. Am Surg. 2020;86(11):1596-1601.
Weaver DJ, Malik AT, Jain N, et al. The modified 5-Item frailty index: a concise and useful tool for assessing the impact of frailty on postoperative morbidity following elective posterior lumbar fusions. World Neurosurg. 2019;124:e626-e632.
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-495.
Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J. 2020;23(3):210-215.
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-1499.
Osler TM, Rogers FB, Hosmer DW. Estimated additional hospital length of stay caused by 40 individual complications in injured patients: an observational study of 204,388 patients. J Trauma Acute Care Surg. 2013;74(3):921-925.
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320-330.
Thakur JD, Corlin A, Mallari RJ, et al. Complication avoidance protocols in endoscopic pituitary adenoma surgery: a retrospective cohort study in 514 patients. Pituitary. 2021;24(6):930-942.
Vogel F, Braun LT, Rubinstein G, et al. Persisting muscle dysfunction in Cushing's syndrome despite biochemical remission. J Clin Endocrinol Metab. 2020;105(12):e4490-e4498.
Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab. 2012;97(5):1702-1711.
Pirlich M, Biering H, Gerl H, et al. Loss of body cell mass in Cushing's syndrome: effect of treatment. J Clin Endocrinol Metab. 2002;87(3):1078-1084.
Terayama R, Ishikawa T, Ishiwata K, et al. Correction of hypercortisolemia with an improved cognitive function and muscle mass after transsphenoidal surgery in an older patient with Cushing's disease. Intern Med. 2022;61(22):3391-3399.
Panayi AC, Orkaby AR, Sakthivel D, et al. Impact of frailty on outcomes in surgical patients: a systematic review and meta-analysis. Am J Surg. 2019;218(2):393-400.
Sharma ST, Nieman LK, Feelders RA. Comorbidities in Cushing's disease. Pituitary. 2015;18(2):188-194.

Auteurs

Matthew C Findlay (MC)

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
School of Medicine, University of Utah, Salt Lake City, Utah, USA.

Robert C Rennert (RC)

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.

Brandon Lucke-Wold (B)

Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.

William T Couldwell (WT)

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.

James J Evans (JJ)

Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Sarah Collopy (S)

Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Won Kim (W)

Department of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.

William Delery (W)

Department of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.

Donato R Pacione (DR)

Department of Neurosurgery, Lagone Medical Center, New York University, New York, New York, USA.

Albert H Kim (AH)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, USA.

Julie M Silverstein (JM)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine, St. Louis, Missouri, USA.

Mridu Kanga (M)

Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, USA.

Michael R Chicoine (MR)

Department of Neurosurgery, University of Missouri, Columbia, Missouri, USA.

Paul A Gardner (PA)

Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Benita Valappil (B)

Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Hussein Abdallah (H)

Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Christina E Sarris (CE)

Department of Neurosurgery, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Benjamin K Hendricks (BK)

Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

Ildiko E Torok (IE)

Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

Trevor M Low (TM)

Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

Tomiko A Crocker (TA)

Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

Kevin C J Yuen (KCJ)

Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

Vera Vigo (V)

Department of Neurosurgery, The Ohio State University, Columbus, Ohio, USA.

Juan C Fernandez-Miranda (JC)

Department of Neurosurgery, Stanford University, Palo Alto, California, USA.

Varun R Kshettry (VR)

Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio, USA.

Andrew S Little (AS)

Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.

Michael Karsy (M)

Global Neurosciences Institute, Philadelphia, Pennsylvania, USA.
Department of Neurosurgery, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.

Classifications MeSH